Back to top
more

Voyager Therapeutics (VYGR)

(Delayed Data from NSDQ)

$3.21 USD

3.21
1,409,306

+0.25 (8.45%)

Updated Aug 4, 2025 03:59 PM ET

After-Market: $3.22 +0.01 (0.31%) 5:28 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -51.43% and 66.26%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of -68.57% and 68.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CytomX Therapeutics (CTMX) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of 210% and 89.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TScan Therapeutics (TCRX) delivered earnings and revenue surprises of -7.41% and 53.59%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Day One Biopharmaceuticals (DAWN) delivered earnings and revenue surprises of -97.14% and 7.74%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

What Makes Voyager Therapeutics (VYGR) a New Buy Stock

by Zacks Equity Research

Voyager Therapeutics (VYGR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

MRK Reports Mixed Keytruda Combo Study Data in Gastroesophageal Cancer

by Zacks Equity Research

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal adenocarcinoma.

Zacks Equity Research

Is it a Good Idea to Invest in Beam Therapeutics Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in BEAM stock now may turn out to be a prudent move.

Zacks Equity Research

Axsome Shares Rise 19% in a Month: What's Driving the Rally?

by Zacks Equity Research

AXSM stock is riding on upbeat preliminary 2024 results. The company's depression drug, Auvelity, drives its top line while Sunosi diversifies its business.

Zacks Equity Research

NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate

by Zacks Equity Research

Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.

Zacks Equity Research

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

by Zacks Equity Research

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.

Zacks Equity Research

J&J's Depression Drug Spravato Gets FDA Nod for Monotherapy Use

by Zacks Equity Research

The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.

Zacks Equity Research

GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer

by Zacks Equity Research

The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.

Zacks Equity Research

Amgen's Lumakras Gets FDA Nod for Expanded Use in Colorectal Cancer

by Zacks Equity Research

The FDA approves Amgen's Lumakras in combination with Vectibix for treating previously treated adults with KRAS G12C-mutated metastatic colorectal cancer.

Zacks Equity Research

Is it a Good Idea to Invest in Stoke Therapeutics Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in STOK now may turn out to be a prudent move.

Zacks Equity Research

MIRM Shares Rise 12% in a Week on Robust Preliminary 2024 Results

by Zacks Equity Research

Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.

Zacks Equity Research

ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals (Revised)

by Zacks Equity Research

Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

Zacks Equity Research

ACAD Seeks EU Nod for Rett Syndrome Drug, Outlines 2025 Pipeline Goals

by Zacks Equity Research

Acadia files regulatory application for trofinetide to treat Rett syndrome in EU. The company also outlines other pipeline goals for 2025-2026.

Zacks Equity Research

TGTX Announces 2024 Preliminary Results, 2025 Goals, Shares Rise

by Zacks Equity Research

TG Therapeutics reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides revenue guidance for 2025 and other pipeline goals.

Zacks Equity Research

SWTX Announces 2024 Preliminary Results, 2025 Goals, Stock Down

by Zacks Equity Research

SpringWorks reports preliminary fourth-quarter and full-year 2024 product revenues. It also provides updates across the commercial portfolio and other pipelines.

Ekta Bagri headshot

3 Biotech Stocks With Promising Gene Therapies to Watch Out in 2025

by Ekta Bagri

We have picked three biotech stocks with promising gene therapies in their portfolios/pipelines that are likely to perform well in 2025.

Zacks Equity Research

Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 152.5% in Voyager Therapeutics (VYGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 64.44% and 95%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of 6.54% and 43.97%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.